Emulin Shows Promise to Reduce Insulin Resistance in Type 1 Diabetics

There are more than 21 million Americans who are currently living with type 1 diabetes.

The most common treatment for type 1 diabetes is two to four injections of different types of insulin daily to help keep blood glucose levels near normal. But now new research shows that there could be a way to offset the onset of diabetes and insulin resistance all together and even reduce the amount of insulin shots a person with type 1 diabetes needs daily.

Two scientists from Florida have discovered a compound they call, Emulin that is naturally derived from flavonols in tropical fruits and vegetables and can be used to protect the body from the negative impact of sugar in the bloodstream.

“Emulin is an ingredient that can be added to any sugar-laden manufactured foods like brownies, colas and cakes,” says Daryl Thompson, scientific director of ATM Metabolics and one of the scientists who discovered the compound. “It then works to protect the body from the glycemic impact of that food without altering the taste.”

An independent study performed by Eurofins Product Safety Laboratories on type 1 diabetic rats treated with Emulin, showed a 20 percent reduction in glucose production. These results indicate that Emulin may have therapeutic potential in the management of both type 1 and type 2 diabetes.

“This is one of the most difficult and extreme research models to test with and I was very
impressed with the outcome,” says Gary Grover, Ph.D., head of pharmacology at Eurofins Product Safety Laboratories. “The only other substance I have seen reduce glucose in this model is insulin.”

The initial research shows Emulin manages glucose metabolism the same way insulin does. Emulin works by reducing the amount of carbohydrates absorbed after meals and reducing the amount of glucose produced by the liver. It also accelerates the removal of excess sugar from the bloodstream, mobilizes carbohydrates from fat cells and increases the sensitivity of insulin receptors in the signaling pathways making insulin more
efficient.

Independent, double-blind human trials are currently being conducted on Emulin, with initial results expected in early June.

For more information about Emulin visit:
http:///www.ATMmetabolics.com or
http://www.Sugardefense.com.

FOR MORE INFORMATION CONTACT:
Karen Ammond- KBC Media kbcmedia@att.net